Stub Period Comparative Data (Unaudited)

6 Months Ended

Dec. 31, 2016

Stub Period Comparative Data (Unaudited)

Stub Period Comparative Data

M. Stub Period Comparative Data (Unaudited)

The condensed consolidated statement of earnings for the six months ended December 31, 2015 is as follows:

	Six Months Ended
	December 31,
	2015
Revenues:
License and milestone fees	$	16,762
Royalty revenue		195
Non-cash royalty revenue related to the sale of future royalties		11,975
Research and development support		1,620
Clinical materials revenue		2,328
Total revenues		32,880
Operating Expenses:
Research and development		73,331
General and administrative		16,383
Total operating expenses		89,714
Loss from operations		(56,834)
Investment income, net		111
Non-cash interest expense on liability related to the sale of future royalties and convertible senior notes		(10,202)
Interest expense on convertible senior notes		—
Other expense, net		(42)
Net loss	$	(66,967)
Basic and diluted net loss per common share	$	(0.77)